Novavax, Inc.
(NASDAQ : NVAX)

( )
NVAX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc. -1.97%73.511.0%$1711.84m
AMGNAmgen, Inc. -0.45%218.211.3%$927.01m
REGNRegeneron Pharmaceuticals, Inc. 0.12%512.962.6%$847.29m
BIIBBiogen, Inc. 1.29%321.051.5%$816.11m
VRTXVertex Pharmaceuticals, Inc. -1.22%246.611.9%$649.45m
ILMNIllumina, Inc. 2.36%287.623.5%$503.42m
MRNAModerna, Inc. -1.73%31.860.0%$501.83m
ALXNAlexion Pharmaceuticals, Inc. -2.36%96.232.0%$301.82m
AAgilent Technologies, Inc. 2.14%78.331.6%$233.31m
INCYIncyte Corp. -1.07%86.812.5%$218.68m
EXASEXACT Sciences Corp. 1.04%67.0621.0%$184.03m
SGENSeattle Genetics, Inc. 0.54%120.326.1%$162.16m
BMRNBioMarin Pharmaceutical, Inc. -0.06%79.554.3%$150.47m
NVAXNovavax, Inc. -0.76%17.05114.7%$134.63m
IMMUImmunomedics, Inc. 6.57%19.6411.9%$129.09m

Company Profile

Novavax, Inc. is operates as a clinical-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. The firm's vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.